AU2017250809B2 - Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer - Google Patents

Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer Download PDF

Info

Publication number
AU2017250809B2
AU2017250809B2 AU2017250809A AU2017250809A AU2017250809B2 AU 2017250809 B2 AU2017250809 B2 AU 2017250809B2 AU 2017250809 A AU2017250809 A AU 2017250809A AU 2017250809 A AU2017250809 A AU 2017250809A AU 2017250809 B2 AU2017250809 B2 AU 2017250809B2
Authority
AU
Australia
Prior art keywords
dose
hu5f9
priming
agent
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017250809A
Other languages
English (en)
Other versions
AU2017250809A1 (en
Inventor
Mark P. Chao
Jie Liu
Ravindra Majeti
Jens-Peter VOLKMER
Irving L. Weissman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2017250809A1 publication Critical patent/AU2017250809A1/en
Application granted granted Critical
Publication of AU2017250809B2 publication Critical patent/AU2017250809B2/en
Priority to AU2024203396A priority Critical patent/AU2024203396A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017250809A 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer Active AU2017250809B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203396A AU2024203396A1 (en) 2016-04-15 2024-05-22 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US62/323,330 2016-04-15
US201662427679P 2016-11-29 2016-11-29
US62/427,679 2016-11-29
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203396A Division AU2024203396A1 (en) 2016-04-15 2024-05-22 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Publications (2)

Publication Number Publication Date
AU2017250809A1 AU2017250809A1 (en) 2018-10-25
AU2017250809B2 true AU2017250809B2 (en) 2024-02-29

Family

ID=60042716

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017250809A Active AU2017250809B2 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
AU2024203396A Pending AU2024203396A1 (en) 2016-04-15 2024-05-22 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203396A Pending AU2024203396A1 (en) 2016-04-15 2024-05-22 Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer

Country Status (12)

Country Link
US (3) US11472878B2 (cg-RX-API-DMAC7.html)
EP (3) EP4349412A3 (cg-RX-API-DMAC7.html)
JP (3) JP7532009B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240016445A (cg-RX-API-DMAC7.html)
CN (3) CN115350276A (cg-RX-API-DMAC7.html)
AU (2) AU2017250809B2 (cg-RX-API-DMAC7.html)
CA (1) CA3019676A1 (cg-RX-API-DMAC7.html)
ES (1) ES2909835T3 (cg-RX-API-DMAC7.html)
PL (1) PL3442578T3 (cg-RX-API-DMAC7.html)
PT (1) PT3442578T (cg-RX-API-DMAC7.html)
SI (1) SI3442578T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017181033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
AU2018351006B2 (en) 2017-10-18 2024-08-29 Forty Seven, LLC Anti-CD47 agent-based ovarian cancer therapy
PT3752190T (pt) * 2018-02-12 2022-11-18 Forty Seven Inc Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
EP3817769A4 (en) * 2018-07-05 2022-03-30 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
KR102871856B1 (ko) 2018-11-26 2025-10-17 포티 세븐, 엘엘씨 c-Kit에 대한 인간화 항체
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
CN114786776A (zh) 2019-09-18 2022-07-22 拉姆卡普生物阿尔法股份公司 针对ceacam5和cd3的双特异性抗体
IL293926A (en) 2019-12-17 2022-08-01 Pfizer Antibodies specific for cd47, pd-l1, and uses thereof
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂
AU2021356708A1 (en) * 2020-10-09 2023-05-11 Sana Biotechnology, Inc. METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT
US12071481B2 (en) 2020-12-23 2024-08-27 D-10 Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
JP2024503822A (ja) * 2021-01-05 2024-01-29 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
EP2249801A2 (en) * 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
HUE060541T2 (hu) 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
PT2804617T (pt) 2012-01-17 2020-09-10 Univ Leland Stanford Junior Reagentes sirp-alfa de alta afinidade
SMT201900453T1 (it) 2012-02-06 2019-11-13 Inhibrx Inc Anticorpi anti cd47 e relativi metodi d'uso
KR102276974B1 (ko) * 2013-02-06 2021-07-13 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
CN105143876B (zh) * 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
US10064925B2 (en) 2013-04-29 2018-09-04 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-CD47 agents to enhance immunization
WO2015050983A1 (en) 2013-10-01 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
BR112016028726A2 (pt) * 2014-06-08 2017-11-07 Remd Biotherapeutics Inc métodos de tratamento de um paciente diagnosticado com diabetes tipo 1, métodos de redução, supressão, atenuação ou inibição de um ou mais sintomas associados com t1d, e métodos de tratamento de um paciente que está em risco de t1d
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
US11053314B2 (en) * 2014-10-10 2021-07-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting CD47
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIE LIU ET AL: PLOS ONE, vol. 10, no. 9, 21 September 2015 (2015-09-21), pages 1 - 23, XP055223677, Retrieved from the Internet DOI: 10.1371/journal.pone.0137345 *

Also Published As

Publication number Publication date
US11718670B2 (en) 2023-08-08
US20230068235A1 (en) 2023-03-02
AU2017250809A1 (en) 2018-10-25
CA3019676A1 (en) 2017-10-19
EP4349412A3 (en) 2024-06-12
EP4349412A2 (en) 2024-04-10
AU2024203396A1 (en) 2024-06-06
CN117695387A (zh) 2024-03-15
KR102505253B1 (ko) 2023-03-02
EP3442578A4 (en) 2019-04-10
ES2909835T3 (es) 2022-05-10
PT3442578T (pt) 2022-05-19
JP2019515899A (ja) 2019-06-13
EP3442578A1 (en) 2019-02-20
US11472878B2 (en) 2022-10-18
CN109152837A (zh) 2019-01-04
JP2022172278A (ja) 2022-11-15
EP3442578B1 (en) 2022-02-09
SI3442578T1 (sl) 2022-05-31
KR20230035435A (ko) 2023-03-13
US20190106491A1 (en) 2019-04-11
KR20240016445A (ko) 2024-02-06
EP4074339A1 (en) 2022-10-19
JP7442591B2 (ja) 2024-03-04
CN115350276A (zh) 2022-11-18
JP2024059764A (ja) 2024-05-01
WO2017181033A1 (en) 2017-10-19
JP7532009B2 (ja) 2024-08-13
KR20180134367A (ko) 2018-12-18
US20230406923A1 (en) 2023-12-21
PL3442578T3 (pl) 2022-06-20

Similar Documents

Publication Publication Date Title
US11718670B2 (en) Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
AU2020264334B2 (en) Targeted therapy for small cell lung cancer
US11891450B2 (en) Anti-CD47 agent-based treatment of CD20-positive cancer
AU2014238105B2 (en) Methods for achieving therapeutically effective doses of anti-CD47 agents
HK40107887A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40080891A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40082292A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40086849A (en) Anti-cd47 agent-based treatment of cd20-positive cancer
WO2023185720A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)